Truist Financial Corporation (TFC)

Truist Financial's stock is trading near the middle of its 52-week range, with the price 2.38% above its 20-day EMA and 1.53% above its 200-day SMA. The most recent earnings report, dated October 16, 2026, was a clear miss: adjusted EPS of $0.56 against an analyst estimate of $1.21, and the shares fell 1.59% in the next session. That miss is the main reason to read the recent rally with care, since the price has held up despite weaker-than-expected profit. For investors, the question now is whether the bank's earnings can recover toward the analysts' expected growth, which is 8.4% for this fiscal year and 17.5% for next.

The October 16, 2026 report is the most important recent event. Adjusted EPS came in at $0.56 against an analyst estimate of $1.21, a miss of 53.72%, and the shares fell 1.59% in the first session. It was the second miss in the last seven reports, and the earlier record is mostly beats: four of seven reports beat the estimate. The July 17, 2026 report, a beat of 13.89% with EPS of $1.23, was followed by a 2.86% drop, the largest first-session move after any of the earlier reports, which shows that a beat has not reliably lifted the stock either.

At a trailing P/E of 12.97, the stock trades at a discount to peers. The sector median P/E is 16.5, so the stock sits 21.4% below it. The price-to-sales ratio of 3.30 is also below the sector median of 3.8, by 13.2%. The discount is partly explained by profitability: return on equity is 8.16%, below the sector median of 13.8%, even though the net profit margin of 26.6% and operating margin of 25.45% are solid. The dividend yield of 4.14%, on an annual dividend of $2.08, is an income feature investors weigh against that lower return.

The price is above both its 50-day SMA of $48.36 and its 200-day SMA of $49.50, and the 50-day average sits 2.31% below the 200-day average. The 14-day RSI is 59.1, in the neutral zone, and the MACD line is positive. Over one year the stock is up 10.92%, and over six months up 7.99%, although the three-month return is down 4.58%. The one-week return is down 1.20%, so the recent drift has been modest.

Of 22 analysts with a current rating, 7 rate the stock buy or strong buy, 12 hold and 3 sell or strong sell. Three months ago, 6 of 21 ratings were buy. Recent actions in October 2026 were mostly reiterations: JP Morgan kept its Underweight rating on October 30, Wolfe Research took over coverage at Peer Perform on October 27, and Citigroup, Stephens & Co., RBC Capital and Keefe, Bruyette & Woods all kept their ratings between October 19 and October 21. Insiders made 7 sales worth $3.2M and 1 open-market purchase worth $1.2M over the last 18 months. Insider sales are often planned in advance or made to cover tax on vesting shares, so they carry less weight than the purchase.

The base case is that the shares trade in a range set by the 200-day average near the bottom and the 52-week high near the top, with direction depending on whether revenue and earnings growth pick up. Revenue grew 5.16% in the latest quarter, year on year, but still trails the sector median of 11.7%, and analysts expect revenue for this fiscal year to shrink 1.1%. A better outcome would come from earnings matching the analysts' forecast of $4.14 for 2026 and $4.87 for 2027, which would support the stock's low valuation at a P/E of 12.97. A weaker outcome would be a continuation of the EPS misses, or a slide through the 200-day SMA, which would bring the 20-day EMA and 50-day SMA into view. The analysts' median 12-month target is $54.00, within a range of $45.00 to $58.00, and the consensus rating is Hold.

Support sits first at the 200-day SMA of $49.50, which is the nearest level below the price and the one most likely to be tested on a pullback. Below it are the 20-day EMA at $49.09 and the 50-day SMA at $48.36, which sit close together and form a shallow support zone. The 52-week low at $43.13 is the deeper floor. On the upside, the 52-week high of $56.20 is the nearest resistance and the first level a rise would meet.